While there have been advances in understanding post-traumatic stress disorder (PTSD) as a disorder and its biological features, unfortunately only one out of five traumatized persons with PTSD reach remission after cycling through evidence-based and/or FDA-approved medications. This is especially unfortunate given that people with PTSD are often from vulnerable populations, or those whose professions entail personal sacrifice. It is clear that new serotonergic antidepressants and atypical antipsychotics will not be sufficient to fix this gap, and new mechanisms of action need to be tested. In the current proposal, the investigators test the hypothesis that mixed amphetamine salts (brand name Adderall), FDA-approved for treating attention deficit hyperactivity disorder (ADHD), can improve PTSD outcomes.

Start Date15 Sep 2026

Sponsor / Collaborator

The University of Chicago

[+1]

NCT07568574

/ Enrolling by invitationNot ApplicableIIT

Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes: A Hybrid Design in a Real-World Setting

Objectives:
The primary objective is to assess the safety and tolerability of medical drugs with the potential to enhance performance (PES) in professional athletes over a 5.5 year period, encompassing a 25-week PES Exposure period and 5 year long term follow-up of period comprehensive health and safety monitoring. The secondary objective is to evaluate the impact of PES on athletic performance through validated sport specific and clinical assessments.
Methods:
This prospective hybrid design study will enrol 60 adult participants, divided into two groups. The first group will receive performance-enhancing substances (PES) directly through the study, administered as Investigational Medicinal Products (IMPs) under comprehensive medical supervision for up to 25 weeks. The second group will include natural athletes and those already using PES prescribed by their own doctors. All substances used in this study are medically approved by national regulatory agencies (e.g., FDA, MHRA, EMA, EDE, etc.), and market authorised.
Participants undergo enrollment and baseline health and performance assessments, prior to a 25 weeks of PES exposure. During the period of PES exposure, participants undergo periodic monitoring of comprehensive physiological biomarkers alongside subjective assessments. Following the PES exposure phase, participants will complete repeat baseline health and performance assessments, followed by a titration phase and, where indicated, post-cycle therapy (PCT) to support the restoration of physiological function toward baseline. The study will conclude with a five-year longitudinal follow-up period to monitor long-term health outcomes. During this phase, participants will undergo annual assessments, including cardiac electrocardiography (ECG), echocardiography, magnetic resonance imaging (MRI), blood and urine biomarkers, routine vital signs, and quality-of-life measures. Additional imaging will include brain functional MRI (fMRI) and vital organ ultrasound at years 1, 3, and 5, with cardiac CT performed as clinically indicated. Athlete safety biomarker assessments, clinical evaluations, and adverse event reporting, will be continuously evaluated by study doctors and with additional safety oversight from a Data Safety Monitoring Board, Independent Medical Commission (a multidisciplinary panel of medical experts), and a Medical Monitor.

Start Date12 Mar 2026

Sponsor / Collaborator-

NCT06853665

/ RecruitingPhase 4IIT

A Pharmaco-Imaging Trial of Mixed Amphetamine Salts for the Treatment of ADHD in Intellectually-intact Youth With Autism Spectrum Disorder

The investigators are conducting a 10-week brain imaging and medication study. They are doing the research to study the response of Attention-Deficit/ Hyperactivity Disorder (ADHD) in youth with Autism Spectrum Disorder (ASD) on extended-release formulation of mixed amphetamine salts (MAS) (also know as Adderall XR). The investigators also want to find out if taking MAS has any effect on the brains of children and adolescents with ADHD and ASD. This study will help researchers better understand how the use of MAS to treat ADHD effects children and adolescents with ASD. The investigators will compare MAS to a placebo. The placebo will look exactly like the MAS capsules but will contain no MAS. During this study, participants may get a placebo instead of MAS. Placebos are used in research studies to see if the study results are due to the study drug or due to other reasons.
Participants with ASD and ADHD will complete 4-weeks of treatment with the study medication or placebo. They will complete bi-weekly study visits virtually via a telemedicine platform with the study doctor and complete questionnaires. On alternating weeks, they will meet with a Massachusetts General Hospital (MGH) study team member to discuss medication adherence and potential side effects. Participants will have the option to attend all study visits in-person if participants prefer. They will also complete baseline and endpoint Magnetic Resonance (MR) scan visits at Massachusetts Institute of Technology (MIT). During the MR Scan visits, they will complete a series of tasks to measure inattention, impulsivity, reward sensitivity, decision-making, and working memory.
Participants without ADHD or ASD will complete eligibility screening with MGH. If eligible, they will be invited to baseline and endpoint MR scan visits at MIT. During the MR Scan visits, they will complete a series of tasks to measure inattention, impulsivity, reward sensitivity, decision-making, and working memory.

Start Date01 Feb 2026

Sponsor / Collaborator

The Massachusetts General Hospital

[+1]

100 Clinical Results associated with Amphetamine Aspartate/Amphetamine Sulfate/Dextroamphetamine Saccharate/Dextroamphetamine Sulfate

100 Translational Medicine associated with Amphetamine Aspartate/Amphetamine Sulfate/Dextroamphetamine Saccharate/Dextroamphetamine Sulfate

100 Patents (Medical) associated with Amphetamine Aspartate/Amphetamine Sulfate/Dextroamphetamine Saccharate/Dextroamphetamine Sulfate

241

Literatures (Medical) associated with Amphetamine Aspartate/Amphetamine Sulfate/Dextroamphetamine Saccharate/Dextroamphetamine Sulfate

28 Apr 2026·JOURNAL OF AMERICAN COLLEGE HEALTH

College students' conceptualization of substance use by peers and themselves: a pilot vignette-based experiment.

Article

Author: Holmes, Ava R ; DeLuca, Joseph S ; Schmidt, Karl T ; Cozens, Annie J

INTRODUCTION:

Substance Use Disorders (SUDs) are prevalent among college students. We assessed whether college students rate scenarios representing symptoms of SUDs differently depending on 1) whether symptoms were ascribed to a friend or to themselves and 2) across drugs.

METHODS:

Each participant read vignette describing use of either tobacco, alcohol, marijuana, Adderall, cocaine, Vicodin, heroin, a non-drug anxiety condition, or a non-drug/non-mental health condition. Participants rated the clarity/believability, degree of substance use, and severity/illness nature. Participants then read and rated another vignette describing the same condition, except "you" engaged in those behaviors and experienced those symptoms.

RESULTS:

Ratings of others' substance use were higher than ratings of personal substance use. Marijuana use was rated as less serious and life-threatening compared to other substances. Interestingly, stress was identified most as a chronic medical condition.

CONCLUSION:

College students might need additional information regarding SUDs to provide peer support and seek treatment themselves.

16 Apr 2026·SUBSTANCE USE & MISUSE

Perceived Risk and Prescription Amphetamine Misuse Among US High School Seniors: A Cross-Sectional Analysis

Article

Author: Maria A. Parker ; Michael X. Peck

BACKGROUND:

Perceived risk, or an individual's perception of the risk associated with a behavior, has been identified as a protective factor against initiating prescription stimulant use. This study examined the association between perceived risk and misuse of prescription amphetamines among US high school seniors.

METHODS:

We analyzed 12th grade data from the Monitoring the Future (MTF) study (2012-2023; n = 16,927). Perceived risk of occasional Adderall use was self-reported, with responses ranging from "No Risk" to "Great Risk." Weighted modified Poisson regression models with robust standard errors assessed the cross-sectional association between perceived risk of Adderall use and past 30-day prescription amphetamine misuse, adjusting for demographic covariates. We also ran sex-stratified models to examine sex differences.

RESULTS:

Approximately a third of students perceived "Low Risk" (32.5%), 25.7% perceived "Moderate Risk," and 41.% perceived "High Risk" of occasional Adderall use. Overall, 2.9% used prescription amphetamines in the past 30 days. Higher perceived risk of occasional Adderall use was significantly associated with lower prescription amphetamine misuse for students perceiving "Low Risk" (APR = 5.65, 95% CI: 4.21, 7.59) and "Moderate Risk" (APR = 1.98, 95% CI: 1.39, 2.83) compared to "High Risk." This association held for both males and females, with no significant sex differences across risk groups.

CONCLUSION:

Perceiving higher risk of occasional Adderall use was associated with lower prescription amphetamine misuse among US high school seniors. Findings support the role of perceived risk as protective and underscore its relevance for early intervention strategies. Future longitudinal studies are needed to clarify the directionality and temporality of this association.

01 Mar 2026·Journal of Attention Disorders

Changes in ADHD Symptoms and Mood Across the Menstrual Cycle in Females Treated With Stimulants: A Pilot Study

Article

Author: Evans, Suzette M. ; Reed, Stephanie C. ; Zaritsky, Rebecca

Objective::

Females represent a growing proportion of adults with ADHD yet remain understudied in the literature compared to males. An important aspect of the experience of females with ADHD is the impact of the menstrual cycle and ovarian hormones on both the symptoms of ADHD and effects of stimulant medications on treating these symptoms.

Method::

In the present pilot study, female participants being treated with amphetamine salts for ADHD ( n = 30) were recruited to complete 35 daily online surveys to track ADHD symptoms, mood, and medication use through the menstrual cycle.

Results::

Results indicated that the degree of ADHD symptoms was significantly associated with menstrual cycle phase with ADHD symptoms being most severe in the menstruation phase and comparatively milder ADHD symptoms in the mid-follicular phase. This difference was positively correlated with subjective changes in negative mood.

Conclusion::

These results indicate that ADHD symptoms vary across the menstrual cycle among females being treated with amphetamine salts for their ADHD, a finding that could inform clinical and prescribing practices for physicians caring for females with ADHD.

144

News (Medical) associated with Amphetamine Aspartate/Amphetamine Sulfate/Dextroamphetamine Saccharate/Dextroamphetamine Sulfate

27 Jul 2026

·www.fiercepharma.com

FDA approves Otsuka’s ADHD drug Simtriyo, teeing up its ‘next major CNS launch’

The FDA has approved Otsuka Pharmaceutical’s once-daily extended-release capsule Simtriyo (centanafadine) for attention-deficit/hyperactivity disorder (ADHD) in patients aged 6 years and older. Approval of the first-in-class norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) gives the Japanese drugmaker its “next major CNS launch” and positions the therapy to become a potential blockbuster in a large, under-penetrated market, according to Jefferies analysts in a July 26 note. Before Simtriyo can launch in the U.S. market, it must clear controlled-substance review by the Drug Enforcement Administration (DEA), a standard, up-to-three-month procedure for all central nervous system stimulants. How the DEA classifies Simtriyo could determine its commercial potential, the Jefferies team noted. A Schedule II designation like what Adderall and Vyvanse have could restrict uptake, while a lower classification could give Simtriyo a competitive edge in a crowded ADHD market, the analysts said. During an investor Q&A in April, Otsuka said it was not clear whether a DEA review would be necessary. The FDA classifies Simtriyo as a stimulant likely because it has dopaminergic effects, the Jefferies team observed in their Sunday note. By inhibiting the reuptake of those neurotransmitters, Simtriyo works by increasing their availability in attention and behavioral pathways. A chronic neurodevelopmental disorder characterized by trouble paying attention and controlling impulsive behaviors, ADHD affects about 7 million children in the U.S. and 15.5 million adults, according to the CDC. Stimulants are the most popular treatments for ADHD, but patients often stop or cycle through different therapies due to a lack of effectiveness, troublesome side effects and changing life demands. “We therefore view the market as capable of supporting multiple treatment classes and believe Simtriyo has an opportunity to expand the overall non-stimulant segment rather than simply take share from existing products such as Qelbree or Strattera,” the Jefferies team wrote. Based on the large market, Otsuka has targeted Simtriyo peak sales of more than 100 billion Japanese yen ($610 million). The company got the drug from its 2017 acquisition of Neurovance for $100 million upfront and up to $150 million in potential development and regulatory milestone payments. Simtriyo proved its worth in four phase 3 clinical trials. It significantly improved ADHD symptoms compared with placebo as measured by the ADHD Rating Scale-5 (ADHD-RS-5) in two pediatric trials and by the Adult ADHD Investigator Symptom Rating Scale (AISRS) in two adult studies. Across the four studies, the most common adverse reactions were rash and decreased appetite in children 6 to 12 years of age; decreased appetite, nausea, rash, headache and abdominal pain in adolescents 13 to 17 years of age; and headache, decreased appetite, insomnia, nausea, dry mouth and diarrhea in adults. A month ago, Otsuka provided positive topline phase 3b results , showing Simtriyo also beat placebo on AISRS in patients with ADHD and comorbid anxiety. “The approval of Simtriyo introduces a novel mechanism of action and expands the range of options available to healthcare professionals and patients,” Lenard Adler, director of the adult ADHD program at NYU Langone Health and an investigator on the centanafadine studies, said in a July 24 statement. “Having more therapeutic choices is important because ADHD is a highly individualized condition and treatment decisions should reflect the unique needs of each patient.” The green light for Simtriyo comes less than a year after the FDA refused to approve Otsuka and partner Lundbeck’s Rexulti as part of a combination for post-traumatic stress disorder due to mixed trial data. The ADHD drug expands Otsuka’s CNS portfolio beyond Rexulti and Abilify Maintena, both atypical antipsychotics approved to treat schizophrenia and other neurological disorders. “ADHD is primarily treated in the community setting, giving Otsuka access to a broad prescriber base and an opportunity to leverage its established US commercial infrastructure,” Jefferies analysts said.

Clinical ResultPhase 3Drug ApprovalAcquisition

27 Jul 2026

·www.biopharmadive.com

FDA scientists question Capricor data; Legend CEO steps down

Today, a brief rundown of news involving Capricor Therapeutics and Legend Biotech, as well as updates from AstraZeneca, Outlook Therapeutics and Otsuka Pharmaceutical that you may have missed.Capricor Therapeutics shares lost nearly two-thirds of their value on Monday after briefing documents indicated that Food and Drug Administration staff reviewers are highly critical of the data supporting the companys experimental cell therapy for Duchenne muscular dystrophy. The FDA previously turned back that cell therapy, deramiocel, but accepted a new application and scheduled a July 29 advisory committee meeting after the company accumulated new data. In documents filed ahead of the panel, FDA scientists noted that Capricors therapy missed its initial Phase 3 study goals, and that its final application included statistical analyses the agency hadnt agreed to. Those changes were unwarranted based on the studys design, powering, and original statistical assumptions, agency reviewers wrote. Capricors findings may have also been compromised by functional unblinding given a distinctive difference in the adverse events observed among drug and placebo recipients, they added.Legend Biotech CEO Ying Huang has stepped down as part of a leadership transition, the cell therapy developer said Friday. Huang has led Legend over the last seven years, during which time the company helped bring the Johnson & Johnson-partnered multiple myeloma treatment Carvykti to market and established a competitive position in in vivo cell therapy development. Still, company shares have lost about half their value over the last year amid crowding competition in multiple myeloma. Alan Bash, the head of Legends Carvykti business unit, will serve as interim CEO while the board searches for a full-time replacement.The incoming CEO, and their interactions/board alignment, will be critical to turning the story around, wrote Oppenheimer analyst Kostas Biliouris, in a Monday note to clients.A few weeks after disclosing a major research setback, AstraZenecahas reported mixed results in two more late-stage readouts. In one Monday announcement, the company revealed its rare disease drug Ultomiris failed a Phase 3 trial in a rare complication related to stem cell transplants. AstraZeneca also said that its antibody-drug conjugate sonesitatug vedotin meaningfully improved survivalwhen compared to standard treatment options in patients with certain gastric cancers, but missed statistical significance on a measure of tumor progression. The former readout erases a potential expansion opportunity for a drug AstraZeneca acquired from Alexion Pharmaceutical and that generated about $2.6 billion in sales between January and June. The latter could still give AstraZeneca a chance to gain an approval for an ADC it licensed in a 2023 deal. Itll share the results with global health authorities.The FDA on Friday finally cleared for use a treatment Outlook Therapeutics developed for a form of age-related vision loss. That medicine, Lytenava, is a version of bevacizumab the active ingredient in Avastin Outlook formulated as an eye drop for the wet form of age-related macular degeneration. Injectable Avastin is widely used off-label to treat wet AMD along with other drugs like Eylea and Vabysmo. Outlook said Lytenava is the first purpose-built ophthalmic formulation of bevacizumab and, while its been approved in Europe and the U.K. for multiple years, it was previously rejected by U.S. regulators three times. Outlook appealed the last rejection and was able to convince the agency earlier this year to change its position.The FDA on Friday also approved a new medicine for attention deficit hyperactive disorder, or ADHD. Called Simtriyo and developed by Otsuka Pharmaceutical, the drug is the first marketed medicine of its kind, targeting three brain chemicals norepinephrine, dopamine and serotonin instead of two, like Adderall or Ritalin. Otsuka said the therapy should be available later this year. '

Phase 3Drug ApprovalCell TherapyClinical ResultExecutive Change

07 May 2026

·www.einpresswire.com

ICAIE Releases New Infographic: The Growing Threat Posed By Illicit Trade of Counterfeit Medicines in Mexico

Diversification by Cartels into Pharmaceuticals Expands the Lucrative Illicit Trade in the Americas Drug cartels' illicit empires now include a growing dominance in the trafficking of fake medicines and counterfeit pharmaceuticals, a multi-billion illicit industry in Mexico and across the Americas.” — David M. Luna WASHINGTON, DC, UNITED STATES, May 7, 2026 / EINPresswire.com / -- ICAIE releases new May 2026 Infographic on illicit trade of counterfeit medicines in Mexico and the Americas by the drug cartels that have also been designated by the United States and Canada as Foreign Terrorist Organizations (FTOs) and Specially Designated Global Terrorists (SDGTs) for their armed violence, drug-fentanyl trafficking, illicit trade and other threats to their respective national security. The Cártel de Jalisco Nueva Generación (CJNG) and other Mexican cartels find diversification into the pharmaceutical sector very lucrative, earning hundreds of millions of dollars from fake, counterfeit, and diverted medicines. – COFEPRIS reports a 300% increase in falsified drug types since 2019. – AMIF estimates that 60% of medicines in Mexico are stolen, expired, falsified, or made without basic quality control. – A 2023 UCLA study found 1 in 3 border pharmacies sold fake meds—68% without prescriptions. – An LA Times investigation found 50%+ of opioid pills tested in Mexico were counterfeit, often containing fentanyl or meth. – Many of these fake pills often mimic Adderall, Xanax, OxyContin, and Percocet—and may contain fentanyl or xylazine. – 12 of 15 Adderall samples contained illicit substances—even in factory-sealed bottles. – In El Santuario, Guadalajara, cartels sell fake meds openly, costing the legal sector over $1B/year. – Vendors and pharmacists are often coerced into selling fakes alongside real medicines. – Many fake drugs target U.S. tourists, disguised as legitimate prescriptions. – Diverted medicines are real but sold illegally, often expired, stolen, or improperly stored. Find ICAIE May 2026 Infographic at: https://icaie.com/2026/05/illicit-trade-of-counterfeit-medicines-in-mexico-diversification-by-cartels-into- pharmaceuticals -expands-the-lucrative-illicit-trade-in-the-americas/ David Manuel Luna International Coalition Against Illicit Economies (ICAIE) email us here Visit us on social media: LinkedIn Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

100 Deals associated with Amphetamine Aspartate/Amphetamine Sulfate/Dextroamphetamine Saccharate/Dextroamphetamine Sulfate

External Link

KEGG	Wiki	ATC	Drug Bank
D11624	Amphetamine Aspartate/Amphetamine Sulfate/Dextroamphetamine Saccharate/Dextroamphetamine Sulfate	-	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Binge-Eating Disorder	United States	Takeda Pharmaceuticals U.S.A., Inc.	23 Apr 2026
Attention Deficit Disorder With Hyperactivity	United States	Teva Women's Health, Inc.	19 Jan 1960

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02979327 (CTgov)	Phase 4	-	30	Adderall (Adderall)	qbtpougjrp(nkrwrtpxgw) = njpqqpqhbh gelvctjdiw (cbgmfhqodx, 2) View more	-	14 Jan 2025
				Placebo (Placebo)	qbtpougjrp(nkrwrtpxgw) = wvtqclrmxz gelvctjdiw (cbgmfhqodx, 2) View more
NCT03945175 (MYDAYIS, CTgov)	Phase 3	Attention Deficit Disorder With Hyperactivity	52	Placebo	vicogpodhd(efmwrcfcsx) = ercmcptfym tzzcuugioa (etajhmxifa, 11.4) View more	-	29 Jun 2023
NCT03810703 (HAP, CTgov)	Phase 1	Bipolar II disorder	93	Placebo oral capsule (Placebo Arm)	qlpvirkbqb(stmineinws) = edfecxqsrl wxdbfmjius (zafddvcmtt, 8.84) View more	-	22 Feb 2023
				d-amphetamine (Amphetamine 10 mg Arm)	qlpvirkbqb(stmineinws) = qxpypvinam wxdbfmjius (zafddvcmtt, 4.46) View more
NCT02803229 (MJ-ADHD, CTgov)	Phase 2/3	Attention Deficit Disorder With Hyperactivity \| Cannabis withdrawal	33	Matched placebo (Placebo)	uxqgdxtpkn = lazzzihrtv sswdmaxkkh (kiuahsiufl, fvhvgdagpe - xeqntyvfmz) View more	-	09 Apr 2021
				Adderall-XR (Adderall-XR)	uxqgdxtpkn = jsvskjgadn sswdmaxkkh (kiuahsiufl, ujmgeznbii - ezdmvywvxy) View more
NCT03325881 (Pubmed) Manual	Phase 3	Attention Deficit Disorder With Hyperactivity	89	SHP465 MAS	cclmikjmii(ghpjnuyrqu): difference = -1.9 (95% CI, -6.8 to 3.1), P-Value = 0.451 View more	Negative	01 Nov 2020
				Placebo
NCT03325894 (CTgov)	Phase 3	Attention Deficit Disorder With Hyperactivity	141	SHP465-112+SHP465 (Group A (Antecedent Studies))	xqjjfsdogx = czgwngppcx qzqyjhicxs (jaujisakcw, qlrgivhcja - rjevujubrf) View more	-	05 Feb 2020
				SHP465 (Group B (Direct Enrollment))	xqjjfsdogx = rwwcfuurgw qzqyjhicxs (jaujisakcw, orxjdhotbg - tlojkownwn) View more
NCT03327402 (CTgov)	Phase 1	Attention Deficit Disorder With Hyperactivity	24	SHP465	ukycobrbzq(ewkwawevge) = lsmjqxjxfu euauozmriu (btqmeboptq, 32.6) View more	-	29 Jan 2020
NCT03530631 (CTgov)	Phase 4	-	4	Adderall (Adderall/Truth)	svydhzoczg = pdaebavagp tlsnmcaycw (fugkpmjzjg, khhnxmimzk - ihfmousevi) View more	-	14 Oct 2019
				Placebo (Placebo/Truth)	svydhzoczg = mvtjngmjre tlsnmcaycw (fugkpmjzjg, xlmwwusyhy - klzqkcdsms) View more
NCT03325881 (CTgov)	Phase 3	Attention Deficit Disorder With Hyperactivity	89	Placebo (Placebo)	acsbmvizri(jgtbtprjxd) = xnwwcilubw baweezwxgl (fjznjusxxf, kffgufvcwc - kfpvcwwrpy) View more	-	13 Aug 2019
				SHP465 (SHP465)	acsbmvizri(jgtbtprjxd) = ogzhwklzed baweezwxgl (fjznjusxxf, zxnpsvwezv - yajnpkvzvf) View more
NCT02466425 (Pubmed \| J Child Adolesc Psychopharmacol) Manual	Phase 3	Attention Deficit Disorder With Hyperactivity	264	SHP465 MAS	gafhuqdjpl(wewdioxhgk): difference = -9.9 (95% CI, -13.0 to -6.8), P-Value = <0.001 View more	Positive	01 Feb 2018
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis